Russ Belville - Sativex (pharmaceutical marijuana) approved in ten more European countries
May 11, 2012 You want medical marijuana? Big Pharma is more than willing to sell it to you…
International expansion of UK firm GW Pharma’s cannabis-based spray Sativex is well underway after a further 10 European countries recommended approval of the drug for multiple sclerosis patients.
Health Authorities in Belgium, Finland, Iceland, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal and Slovakia have now given the go-ahead for Sativex (delta-9-tetrahydrocannabinol and cannabidiol), completing its Mutual Recognition Procedure in Europe.
This means that Sativex can be marketed in these countries as an add-on therapy for the treatment of moderate to severe spasticity due to MS in patients who have not responded adequately to other medication, and launches are expected from the end of this year onwards.
Sativex has already been approved in the UK, Spain, and Germany and other European countries:
GW says marketing partner Almirall expects to introduce the drug in the German market in July and before the end of 2011 in Denmark and Sweden. Sativex is scheduled to be launched in Italy, Czech Republic and Austria in 2012.
Read More: